Probably because "Biogen offered to buy Sage, its marketing partner on Zurzuvae, a pill to treat postpartum depression, for $469 million — less than the $569 million in cash that Sage has on hand as of September. The lowball offer is unlikely to be accepted, but Sage also has little leverage after a series of clinical failures last year wiped out its research pipeline and decimated its stock price."
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.003(22.7%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.1¢ | $298.4K | 24.29M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 4870164 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 10882572 | 45 |
View Market Depth
| Last trade - 12.12pm 27/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |